NPPA’s recent move to cap the price of 42 nonscheduled cancer drugs has evoked mixed reactions from the industry. While some berated it as a hasty decision, others have lauded it and believe that it will be beneficial in the long run
The price cap on 42 non-scheduled cancerdrugs by the National Pharmaceutical Pricing Authority (NPPA), which was set to be a relief for cancer patients is just a pyrrhic victory, inform experts, as cancer patients still feel the sting of ‘out-of-pocket-expenses.’ Some stakeholders — drug manufacturing firms, hospitals and pharmaceutical associations — believe that the move was implemented in haste and it needs a ‘re’view.
Elaborating on whether the move is beneficial for pharma companies, Kiran Mazumdar Shaw, CMD, Biocon, believes that if such decisions are made in “fits and starts”, though with an intention to fix something, the goal remains largely unfulfilled.
“I think we need to look at all our policies in a holistic way. Just reducing drug prices doesn’t really solve the problem. We have got to look at all the healthcare costs holistically if we really want to build enduring sustainable models,” she adds.
Agreeing with her, Rakesh Pandey, CMD, Bravo Pharmaceuticals, a drug manufacturing and distribution company with sales in India, Central Asia and Eastern European countries, says that this step taken by NPPA is not good in terms of business for the pharma companies which are export-oriented and their target market is India. “This move gains significance in the government’s attempt to provide affordable healthcare. The authority has noted that despite the fact that India is the pharmacy of the world, out-of-pocket expenses on medicines is the largest cause for pushing families beyond the poverty threshold. Pharma companies, on the other hand, can now target the volume-based big markets otherwise it’s not going to benefit them,” he points out.
Export, import and discounts
Esta historia es de la edición May 01-15, 2019 de Express Pharma.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición May 01-15, 2019 de Express Pharma.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Powerful Process Control with IND500x Weighing Indicators
Ensuring consistent quality in hazardous environments, particularly in Ex-Areas (Zone 1/21, Division 1), is a critical aspect of industrial operations. The IND500x weighing indicators from METTLER TOLEDO provide a robust solution for these challenging settings, offering optimized safety and productivity.
Ensuring clean room integrity with prime clean reset high-speed doors
Prime Clean Reset high-speed doors ensure airtight seals, minimising air permeability and contamination in clean rooms. Designed for sensitive environments, they enhance operational efficiency and meet rigorous regulatory standards, making them ideal for pharmaceutical and biotech industries
Complete environmental monitoring solution - testo Saveris Pharma
There are several critical applications in the industry like research and development that demand for continuous & reliable monitoring of important environmental parameters.
Adaptive Manufacturing:-The new flexibility in medical device assembly
Unlike traditional, rigid production lines, B&R's adaptive machines seamlessly adjust to the requirements of each device, dynamically adapting to each unique process
Reshaping pharma safety with active packaging innovations
CILICANT is revolutionising active packaging with solutions tailored for the most sensitive formulations. Meet the innovators driving stability, safety, and impurity control in pharma packaging at CPhI India
UNLOCKING GROWTH FRONTIERS
Vadodara Pharma Summit 2024 brought together industry leaders and experts to highlight the city's pivotal role in India's pharma landscape and explore collaborative strategies to strengthen India's pharma innovation ecosystem
Optimising cloud provisioning for pharmaceutical compliance and operational excellence
Suresh Perikala, Senior Engineering Lead - DevOps and Cloud Engineering Practice, Altimetrik
Accelerating pharma's sustainability efforts
Avinaw Prasad, Director, Climate Change & Sustainability, Deloitte India explains why integrating sustainability into the core pharma business strategy is essential for long-term success, analyses key focus areas and policy pushes which can incentivise companies to further evolve on the sustainability path
Drug Repurposing: Unlocking access to rare solutions
Drug repurposing, a quick, cost-effective path to deliver existing treatments to patients, can serve to expedite and expand healthcare access for patients with rare diseases
Optimising spend, maximising growth
Express Pharma, in partnership with IPA and CHEMEXCIL, powered by SAP, recently organised a thought leadership conclave on 'Reimagining spend management and supply chain' where cross functional experts explored strategies to drive value through supply chain transformation